

# INTRAHEPATIC CXCR3 AND CXCL10 ARE ASSOCIATED WITH LIVER DISEASE IN HIV-HBV CO-INFECTION

Singh KP<sup>123</sup>, Audsley JA<sup>1</sup>, Crane M<sup>1</sup>, Tennakoon S<sup>1</sup>, Braat S<sup>4</sup>, Revill PA<sup>1,5</sup>, Avihingsanon A<sup>6</sup>, Lewin SR<sup>1,3</sup>

<sup>1</sup>The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC 3000, Australia, <sup>2</sup>Victorian Infectious Diseases Service, Royal Melbourne Hospital, <sup>3</sup>Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia, <sup>4</sup>Melbourne School of Population and Global Health and Melbourne Clinical and Translational Sciences Platform (MCATS), The University of Melbourne, Parkville, VIC, Australia, <sup>5</sup>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute of Infection and Immunity, <sup>6</sup>HIV-NAT Research Collaboration, Bangkok, Thailand

**Background:** HIV infection significantly alters the natural history of chronic hepatitis B (HBV). Compared to HBV mono-infection, HIV-HBV infected individuals experience accelerated progression of liver disease and increased liver-related mortality that persists on HBV-active antiretroviral therapy (ART). We investigated the hypothesis that increased microbial translocation (MT) and chronic immune activation (IA) secondary to HIV infection was a driver for liver fibrosis in HIV-HBV co-infected individuals.

**Methods:** Liver biopsies and plasma were collected from a HIV-HBV coinfecting individuals (n=37) naïve to ART. Liver fibrosis was assessed using transient elastography (TE) and liver biopsy. Lipopolysaccharide (LPS), soluble (s) CD14, CCL2 and CXCL10 were measured in plasma. Liver biopsies were analysed by immunohistochemistry (IHC) for HIV RNA and CXCL10 and qPCR for CXCL10 with its receptor CXCR3, interferons  $\alpha$ ,  $\beta$  and  $\gamma$ .

**Results:** The cohort was young, predominantly male, HBeAg positive with median CD4<sup>+</sup> T cell count of 360 (210-470) cells/microL. Liver disease at baseline was mild with >80% classified as  $\leq 2$  by TE. HIV RNA was detected in liver but was infrequent and largely localized to T-cells. Intrahepatic CXCR3 and CXCL10 were strongly correlated and significantly associated with histological and TE measures of liver fibrosis and ALT, AST and GGT (Spearman rho 0.3-0.61). AST was significantly associated with all plasma markers except plasma LPS and IFN- $\gamma$ . Plasma LPS and sCD14 were not associated with liver fibrosis.

**Conclusion:** Markers of MT were not associated with liver disease in HIV- HBV co-infected individuals. However, CXCR3 and CXCL10 were significantly associated with fibrosis and liver enzyme elevation consistent with infiltration of CXCR3<sup>+</sup> cells such as activated T-cells driving liver disease. CXCR3 and CXCL10 should be investigated as novel targets to minimize liver disease in HIV-HBV co-infection